检索结果 - Seiichi Hayato

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

    Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses 由 Toshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo, Takuya Suzuki, Takuji Okusaka, Kenji Ikeda, Hiromitsu Kumada

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

    Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma 由 Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga, Hideki Ueno, Toshiyuki Tamai, Takuya Suzuki, Seiichi Hayato, Tadashi Kadowaki, Kiwamu Okita, Hiromitsu Kumada

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

    Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease 由 Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad J. Swanson, Sanae Yasuda, Ziad Hussein

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma 由 Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, Hiromitsu Kumada

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

    Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer 由 Naomi Kiyota, Martin Schlumberger, Kei Muro, Yukio Ando, Shunji Takahashi, Yasukazu Kawai, Lori J. Wirth, Bruce Robinson, Steven I. Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies 由 Robert J. Motzer, Matthew H. Taylor, T.R. Jeffry Evans, Takuji Okusaka, Hilary Glen, Gregory M. Lubiniecki, Corina E. Dutcus, Alan D. Smith, Chinyere E. Okpara, Ziad Hussein, Seiichi Hayato, Toshiyuki Tamai, Vicky Makker

    出版 2022
    获取全文
    Revisão
    加到收藏夹
    Saved in:

检索工具: